Subtherapeutic oral anticoagulant therapy: Frequency and risk factors

Eva K. Rombouts; Frits R. Rosendaal; Felix J. M. van der Meer

doi:10.1160/TH08-09-0626

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(03): 552-556
DOI: 10.1160/TH08-09-0626

New Technologies, Diagnostic Tools and Drugs

Schattauer GmbH

Subtherapeutic oral anticoagulant therapy: Frequency and risk factors

Eva K. Rombouts

¹Department of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, the Netherlands

,

Frits R. Rosendaal

¹Department of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, the Netherlands

²Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands

,

Felix J. M. van der Meer

¹Department of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, the Netherlands

› Author Affiliations

Abstract

Summary

Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.

Keywords

Oral anticoagulants - anticoagulant stability - INR

Full Text

References

References
1 Atrial Fibrillation Investigators.. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
2 Lagerstedt CI, Olsson CG, Fagher BO. et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 515-518.
3 van Walraven C, Hart RG, Singer DE. et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. J Am Med Assoc 2002; 288: 2441-2448.
4 Ansell J, Hirsh J, Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S.
5 Reynolds MW, Fahrbach K, Hauch O. et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126: 1938-1945.
6 Cannegieter SC, Rosendaal FR, Wintzen AR. et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
7 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
8 Go AS, Hylek EM, Chang Y. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. J Am Med Assoc 2003; 290: 2685-2692.
9 Kalra L, Yu G, Perez I. et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. Br Med J 2000; 320: 1236-1239.
10 Wyse DG, Waldo AL, DiMarco JP. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
11 Hylek EM, Skates SJ, Sheehan MA. et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546.
12 Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
13 Stroke Prevention in Atrial Fibrillation Investigators.. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-539.
14 Connolly SJ, Laupacis A, Gent M. et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-355.
15 Ezekowitz MD, Bridgers SL, James KE. et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-1412.
16 Petersen P, Boysen G, Godtfredsen J. et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-179.
17 Samsa GP, Matchar DB, Goldstein LB. et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000; 160: 967-973.
18 Penning-van Beest FJ, van Meegen E, Rosendaal FR. et al. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001; 86: 569-574.
19 Penning-van Beest FJ, van Meegen E, Rosendaal FR. et al. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001; 69: 451-457.
20 Palareti G, Legnani C, Guazzaloca G. et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005; 129: 72-78.
21 Cadiou G, Varin R, Levesque H. et al. Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department. Thromb Haemost 2008; 100: 685-692.
22 Szklo M, Nieto FJ. Epidemiology: beyond the basics. In: Basic Study Designs in Analytical Epidemiology. Jones and Bartlett Publishers; 2004. pp. 3-51.
23 Gadisseur AP, van der Meer FJ, Adriaansen HJ. et al. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002; 117: 940-946.
24 Fihn SD, Gadisseur AA, Pasterkamp E. et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90: 260-266.
25 Pattacini C, Manotti C, Pini M. et al. A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). Thromb Haemost 1994; 71: 188-191.